Summary
The relative bioavailability of the newly developed formulation of co-dergocrine mesylate (Hydergine spezial, 1×4 mg) was determined in elderly patients under steady state conditions, with conventional Hydergine forte tablets (2×2 mg) as a reference. Both formulations were given once a day for 8 days in a randomised cross-over design. The areas under the curve showed that the bioavailability of the new tablet was about 30% higher (28±6.3%) than that of Hydergine forte. The peak plasma concentration was reached 3±0.9 h after administration. Because of its greater relative bioavailability higher plasma levels were found 2–24 hours after the Hydergine spezial formulation than after Hydergine forte tablets.
This is a preview of subscription content, log in via an institution to check access.
References
Aellig WH, Nüesch E (1977) Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol Ther Toxicol 15: 106–112
Berde B, Schild HO (1978) Handbook of experimental pharmacology, vol. 49. Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 758–768
Bock KD, Welzel D, Dennler HJ (1982) Die Wirkung von Codergocrinmesilat bei älteren Hypertonikern. Muench Med Wochenschr 124: 1095
Franz JM, Vonderscher JP, Voges R (1980) Contribution to the intestinal absorption of ergot peptide alkaloids. Int J Pharmacokinet 7: 19–28
Horsch A (1982) Prüfung der blutdrucksenkenden Wirkung von Hydergin spezial unter stationären Bedingungen. Eine Pilotstudie. Therapiewoche: 32: 3882–3886
Humbert HD, Lavène D, Guillaume MF, Kiechel JR (1981) Pharmacokinetics and bioavailability with two ergot peptide alkaloids: co-dergocrine and dihydrogergotamine. In: Aiache JM, Hirtz J (eds) Proceedings of the First European Congress of Biopharmaceutics and Pharmacokinetics, Clermond-Ferrand. Technique et Documentation, Paris, vol. 1, pp 334–340
Kiechel JR (1982) Biotransformation of drugs in old age. Gerontology 28 [Suppl 1]: 101–112
Kiechel JR, Lavène D, Humbert H, Guillaume MF (1982) Untersuchungen zur Bioverfügbarkeit von Hydergin spezial. Med Welt 33: 1168–1170
Loew DM, Weil C (1982) Hydergine in senile mental impairment. Gerontology 28: 54–74
Nimmerfall F, Rosenthaler J (1980) Significance of the gobletcell mucin layer, the outermost luminal barrier to passage through the gut wall. Biochem Biophys Res Commun 94: 960–966
Sachs L (1978) Angewandte Statistik, 5. Auflage, Springer Heidelberg Berlin New York, p 201, 244–246
Shand DG (1982): Biological determinants of altered pharmacokinetics in the elderly. Gerontology 28 [Suppl 1] 8–17
Sheiner LB (1981) Elsfit. A Program for the extended least squares FIT to individual pharmacokinetic data. Users manual. A technical report of the Division of Clinical Pharmacology of California, SF, CA 94143
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sörgel, F., Abisch, E., Dennler, H.J. et al. Steady state bioavailability of a new oral formulation of Hydergine® in geriatric patients. Eur J Clin Pharmacol 26, 133–135 (1984). https://doi.org/10.1007/BF00546722
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546722